Combination of Immunotherapy and VEGF Inhibitor Improves Survival in Hepatocellular Carcinoma #ESMOAsia19

da Salute H24 — 22 novembre 2019 alle 11:32


Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019… Continua »

AntonioCaperna

Scrivi un commento